“Global Human Microbiome Therapeutics market set to grow to $1bn by 2024” says new Visiongain report

24 April 2019
Pharma

Visiongain has published a new pharma report Global Human Microbiome Therapeutics Market Forecast 2019-2029: Gastrointestinal Disorders, Infectious Diseases, Metabolic Disorders, Dermatological Conditions, Other Disorders.

A specialist sector within the overall pharmaceutical industry, the human microbiome-therapeutic market is dominated by a relatively small number of companies. The market holds enormous opportunities for growth in key therapeutic areas. Some of the Phase III drugs are expected to be launched in the first half of the forecast period while few Phase II drugs are expected to be launched in second half of the forecast period. We expect growth in all key sectors of the market during the forecast period.

This report profiled the selected companies: 4D Pharma, AOBiome Therapeutics, C3J Therapeutics, Caelus Health, Enterome Bioscience, Ferring Pharmaceuticals, Finch Therapeutics/Crestovo, IGEN BIOTECH GROUP, Immuron, Intrexon Corporation, MaaT Pharma, MatriSys Biosystem and other companies.

The lead analyst commented that "The prime opportunity for microbiome therapeutics is to fulfil the unmet clinical needs in various indications. The current therapies in some of the indication may provide symptomatic relief but cannot cure the disease or have adverse side effects. The microbiome industry is in nascent stage but developing rapidly. The first human microbiome therapeutics is expected to launch in 2020. Various clinical data suggests that the use of microbiome-based therapies is likely to cause fewer side effects than the use of traditional pharmaceuticals, further enhancing their market potential."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever